Chat with us, powered by LiveChat Thailand Medical News - HIV / AIDs
HIV / AIDs
Read all about the latests in HIV/Aids research and treatment protocols and also developments made into various specific components of managing this disease that is by itself also evolving.
Presented by
Source: University of California  Nov 01, 2018
Researchers are investigating other antiretrovirals, antibodies, injectables, implants, vaginal rings, vaginal films and other products Oral pre-exposure prophylaxis (PrEP) based on tenofovir disoproxil fumarate /emtricitabine   (Truvada)has set a high bar for prevention effectiveness, but a range of alternative PrEP products are in development, Raphael Landovitz of the University of ...
Source: IDWeek2018  Oct 25, 2018
The newest once-daily, all-in-one HIV combination pills can maintain undetectable viral load for two years and counting, according to a set of studies presented at ID Week 2018 this month in San Francisco.   Two phase 3 clinical trials showed that most people who took the bictegravir-based Biktarvy co-formulation or the doravirine-based Delstrigo pill for first-line t...
Source: Boston University School of Medicine  Aug 28, 2018
A new study has shown that genital warts may promote HIV sexual transmission and, in turn, their treatment and prevention could help decrease the spread of the disease.  HIV infecting a human cell. Credit: NIH Human Papillomavirus (HPV) is a common and highly infectious condition transmitted between persons during sexual skin-to-skin contact. It has more than 100 strains identified, with s...
Source: Massachusetts General Hospital, Boston  Aug 08, 2018
Raza M. Alvi, M.D., from Massachusetts General Hospital in Boston, and colleagues compared characteristics, cardiac structure, and outcomes in 394 persons with HIV and heart failure who were receiving PI (145 patients) versus non-PI (NPI; 249 patients) therapy. PI-based antiretroviral therapy contained boosted-dose ritonavir.   Ritonavir-boosted protease inhibitor (PI) therapy is a...
Source: The Lancet  Jul 22, 2018
Study paves way for better use of primate models in HIV vaccine development   The mosaic vaccine HIV-1 vaccine produced comparable immune responses in both humans and rhesus monkeys, a phase I/IIa trial found.   In humans, the vaccine was safe and produced antibody responses and T-cell responses, and in monkeys, the vaccine not only produced similar immune responses, but protected ...